Skip to main
VNRX

Volitionrx Limited (VNRX) Stock Forecast & Price Target

Volitionrx Limited (VNRX) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

VolitionRX is a company that is utilizing its Nucleosomics platform to develop simple and effective blood tests to diagnose and monitor life-altering diseases, including some cancers and diseases associated with NETosis, with a focus on human diagnostics. Additionally, the company has a subsidiary focused on diagnostics and monitoring. The recent data from a blinded validation cohort showed highly encouraging detection rates for all cancer stages, with a sensitivity of 93% and specificity of 95%. Volition is the first liquid biopsy company to focus on circulating cell free nucleoproteins, and the results in early-stage cancers could help secure potential licensing partners. The clinical implications of using circulating nucleosomes as biomarkers for disease monitoring are significant, particularly for the high-risk population of trauma patients. With limited tools for risk stratification currently available, Volition's approach could offer a differentiated pathway for treatment decisions and preventive strategies. However, risk factors such as clinical/regulatory, partnership and financial, commercial, legal and intellectual property, and market share risks must also be considered.

Bears say

VolitionRX is facing several challenges, including the need to regain compliance with NYSE American requirements and improve commercial traction, as well as the potential negative effects of their recent reverse stock split. Additionally, their valuation is currently overstated and there are significant risks to achieving their 12-month price target. While the company is making progress in terms of partnerships and validation studies, it remains to be seen whether they can successfully translate this into commercial success and widespread adoption of their diagnostic tests.

Volitionrx Limited (VNRX) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Volitionrx Limited (VNRX) Forecast

Analysts have given Volitionrx Limited (VNRX) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Volitionrx Limited (VNRX) has a Strong Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Volitionrx Limited (VNRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.